Reporting owner · CIK 0001914560

Martini Jeffrey S

SEC Form 4 history for the last 180 days across 1 company, 19 transactions and 1 filing.

CSOChief Scientific OfficerPALVELLA THERAPEUTICS, INC.
Open-market transaction mix0% buys0 buys · 13 sales

Period: Last 180 days

Trade dates in this period: Nov 10, 2026 – Nov 11, 2026

Transaction history, summary figures and purchase returns cover the last 180 days. Earlier activity is excluded from those sections.

Filings1Form 4 records
Buying$00 purchases
Selling$2.08M13 sales
Net value−$2.08MBuys minus sells · disclosed values

Latest insider transactions

Form 4 filings from the last 180 days.
Martini Jeffrey S transactions · 20 per page
CompanyActivityDisclosed valueFiled (ET)
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
Derivative securitySEC filing ↗
$0View disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$34.0kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$101kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$201kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$189kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$243kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$271kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$61.2kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$138kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$93.0kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$33.6kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$250kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$274kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$239kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
−$16.3kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$19.4kView disclosure →
PVLAPALVELLA THERAPEUTICS, INC.
CSO
CSO. Role codes can represent multiple titles; the list does not include the filing title.
Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Pre-planned (10b5-1)
10b5-1 plan language detected in footnotes; absence does not prove a discretionary trade.
SEC filing ↗
$32.1kView disclosure →

Latest Form 4 facts

Quick context from source filings

Latest open-market transaction

The insider reported a sale at PALVELLA THERAPEUTICS, INC. on Nov 11, 2026 valued at $33,956.44.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Monthly open-market activity

Last 1 reported month · purchases and sales

View exact monthly values
Monthly open-market source values
MonthPurchasesSalesBuy valueSale valueNet value
Nov 2026013$0$2,083,076.38−$2,083,076.38

Net value is disclosed purchases minus sales, not profit. A dash means the value is unavailable.

Ownership and transaction size

Ownership and ticket size

Average P/S size$160k
Median P/S size$189k
Direct19
Indirect0
Nov 11, 2026exercise

Associated companies

Counts cover all available history, including outside the summary period

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
No open-market purchases in the last 180 days

A 90-day purchase return requires an open-market buy. None is recorded in the last 180 days. Purchases filed earlier are outside the visible history and are not included.

Disclosed ownership

How reported shareholdings evolved

Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.

16 observations · Nov 10, 2026 – Nov 11, 2026. Window ends at the latest available report, not today.

Selected observation · Nov 11, 20260 shares reported
Inspect transaction
View exact observations and source transactions
Transaction dateShares held afterFiledSource
Nov 10, 20264,266Nov 12, 2026View transaction
Nov 10, 20266,250Nov 12, 2026View transaction
Nov 10, 20266,150Nov 12, 2026View transaction
Nov 10, 20264,701Nov 12, 2026View transaction
Nov 10, 20263,050Nov 12, 2026View transaction
Nov 10, 20261,550Nov 12, 2026View transaction
Nov 10, 20261,350Nov 12, 2026View transaction
Nov 10, 2026800Nov 12, 2026View transaction
Nov 10, 20260Nov 12, 2026View transaction
Nov 11, 20266,250Nov 12, 2026View transaction
Nov 11, 20264,600Nov 12, 2026View transaction
Nov 11, 20263,133Nov 12, 2026View transaction
Nov 11, 20262,000Nov 12, 2026View transaction
Nov 11, 2026800Nov 12, 2026View transaction
Nov 11, 2026200Nov 12, 2026View transaction
Nov 11, 20260Nov 12, 2026View transaction

Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.

Martini Jeffrey S Insider Activity FAQ

SEC Form 4 context

Who is Martini Jeffrey S?

Martini Jeffrey S is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001914560.

Which companies has Martini Jeffrey S reported transactions for?

PALVELLA THERAPEUTICS, INC.

When was Martini Jeffrey S's latest insider buy?

No open-market insider purchase is recorded in the last 180 days. Earlier filings are outside the visible history.

When was Martini Jeffrey S's latest insider sale?

The insider reported a sale at PALVELLA THERAPEUTICS, INC. on Nov 11, 2026 valued at $33,956.44.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

The profile shows average and median 90-day stock returns after open-market purchases when price coverage is available. These are unadjusted stock returns, not realized trading gains. Win rates, benchmark-adjusted returns and conviction scores are not calculated.